Novartis announced that it has entered into an exclusive global licensing and research collaboration agreement with Regenerex LLC, a biopharmaceutical company based in Louisville, Ky., for use of the company's novel Facilitating Cell Therapy (FCRx) platform.
AstraZeneca announced enrollment of the first patient in the Phase 3 SOLO trial clinical program for olaparib, an innovative oral poly ADP ribose polymerase (PARP) inhibitor being investigated for the treatment of BRCA mutated ovarian cancer. The SOLO 1 study is being conducted in collaboration with the Gynecologic Oncology Group and the SOLO 2 study with the European Network of Gynaecological Oncological Trial Groups.
Takeda Pharmaceutical Co. Ltd. and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A. Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.
Shares of Agenus fell sharply Thursday on unsuccessful clinical trial results for a cancer treatment that included its compound that is designed to make drugs more effective. British drugmaker GlaxoSmithKline PLC is studying cancer treatments that include Agenus' SQ-21 Stimulon vaccine adjuvant.
Astex Pharmaceuticals Inc. said Thursday that it reached a deal to sell itself to Otsuka Pharmaceutical Co. for about $804.1 million in cash. Under the terms of the agreement, Otsuka will pay $8.50 per share for the Dublin, Calif., drug developer. The price represents a 3 percent premium over Astex's Wednesday closing share price of $8.27.
While herpesviruses infect most animals– including humans– with incurable disease, researchers have found a genetic trail to thwart its reproductive powers, cutting its infective powers by a factor of up to 10,000. The technique involves locking up virus DNA inside its viral carriers, reports the new study that opens a much-needed new pathway for antiviral drug development.
A protein at the center of Parkinson’s disease research now also has been found to play a key role in causing the destruction of bacteria that cause tuberculosis, according to a research team. The protein, named Parkin, already is the focus of intense investigation in Parkinson’s disease, in which its malfunction is associated with a loss of nerve cells.
Johns Hopkins scientists have identified a molecular marker called “Mig 6” that appears to accurately predict longer survival- up to two years- among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.
Rigel Pharmaceuticals said it will end some of its drug development programs and eliminate about 30 jobs, after its drug fostamatinib didn't work as a treatment for rheumatoid arthritis. Rigel said it wants to concentrate on drugs that are most likely to gain marketing approval in the near future.
Pozen said that Sanofi will handle U.S. marketing of its experimental cardiovascular drugs PA8140 and PA32540. The French drugmaker will pay Pozen $15 million upfront, and Pozen could get another $20 million in payments based on milestones before approval of the products.
Endo Health Solutions said that regulators accepted for review new data for its long-acting testosterone injection Aveed and will make a ruling on the drug by Feb. 28. The Food and Drug Administration asked Endo for more information in May.
A Phase 1 clinical trial (SAV CT 01) of the first and only preventative HIV vaccine based on a genetically modified killed whole virus (SAV001-H) has been successfully completed with no adverse effects in all patients, Western and Sumagen Canada Inc. announced.
Research into personalized medicine is being led by a University of Greenwich team. Currently, many medicines which are prescribed to patients either do not work properly or have some significant side effects. The aim of personalized medicine, sometimes called precision medicine, is to ensure that the most appropriate medicine is given to each patient and that the medicine is both effective and safe.
Abbott announced promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack.
Researchers have identified a compound that dramatically bolsters learning and memory when given to mice with a Down syndrome-like condition on the day of birth. As they report, the single-dose treatment appears to enable the cerebellum of the rodents’ brains to grow to a normal size.